News

Civitas Resources Class Action Lawsuit Update for Investors

Civitas Resources Class Action Lawsuit Update for Investors

Civitas Resources Investors: Important Class Action Update

The Gross Law Firm is reaching out to shareholders of Civitas Resources, Inc. (NYSE: CIVI) to remind them of a significant class action lawsuit pending against the company. This notice is particularly important for those who purchased shares of CIVI during the specified class period.

Class Period Details

Investors should be aware that the class period for this lawsuit extends from February 27, 2024, to February 24, 2025. The Gross Law Firm encourages all shareholders who acquired shares during this time to consider their legal rights and options.

Allegations Against Civitas

Several serious allegations have been made against Civitas Resources that may affect its future and the investment decisions of its shareholders. It has been suggested that Civitas is likely to reduce oil production in 2025 significantly, primarily because of declines following its peak production in the DJ Basin during the last quarter of 2024. The company's current oil production levels seem unsustainable without acquiring new development acreage, which could lead to considerable debt and force the company to sell assets. Additionally, there are concerns about possible workforce layoffs as part of necessary cost-cutting measures.

Shareholders believe that Civitas has been overstating its financial and operational capabilities, leading to misleading public statements about its business condition at all relevant times.

Key Deadline Approaching

One critical date for shareholders to remember is July 1, 2025. This is the deadline for registering as a lead plaintiff in the class action lawsuit. Participation in this case doesn’t require serving as a lead plaintiff, meaning shareholders can still be involved in the legal proceedings.

Steps for Participation

Civitas shareholders who wish to secure their interests and stay updated on the case's developments should register as soon as possible. Those who participate will be enrolled in a portfolio monitoring service, offering occasional updates on the status of the lawsuit. Importantly, this process entails no financial obligation for shareholders.

Why Choose The Gross Law Firm?

The Gross Law Firm is a highly regarded national class action law firm devoted to protecting the rights of investors fallen victim to deceptive business practices. The firm is committed to holding companies accountable, ensuring compliance with ethical business standards, and advocating for investors impacted by misleading information. Their services aim to help recover losses suffered by shareholders due to inflated stock prices resulting from fraudulent practices and false statements by company officials.

Contact Information

For additional inquiries or to engage their services, shareholders can contact The Gross Law Firm directly:

The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Phone: (646) 453-8903

Frequently Asked Questions

What is the class action lawsuit against Civitas about?

The lawsuit concerns allegations that Civitas misled investors about its production capabilities and financial health, affecting stock prices.

Who can participate in the class action lawsuit?

Shareholders who purchased shares of Civitas Resources during the class period, from February 27, 2024, to February 24, 2025, can participate.

What are the deadlines for this class action?

The deadline to register as a lead plaintiff is July 1, 2025, but shareholders can join the lawsuit without being a lead plaintiff.

How can I stay updated on the case?

Registered shareholders will receive updates through a portfolio monitoring system that tracks the case's progress.

Is there any cost to participate?

Participation in this class action does not involve any fees or costs for shareholders.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 110

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Dental Exams Are Routine Until They Catch Something Early

Updated Category News Views 60

A mouth can look perfectly fine right up until it does not. That is the unglamorous value in the dental exam and X-rays visit described by Dr. Eric Runyon of Smiles Unlimited in Belton, Missouri: it is a structured look for trouble before pain, swelling, or a cracked tooth forces the issue. Nobody throws a parade for preventive care, but waiting for symptoms has a habit...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
es